CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED
ActiveKey figures
† CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.
Like most small UK companies, CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2025Sector comparison
SIC 72190Where the company stands among the 5,632 active companies whose first SIC code is 72190 (Other research and experimental development on natural sciences and engineering).
- CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED£3.5bn
- ELLISON INSTITUTE OF TECHNOLOGY, OXFORD LIMITED£1.4bn
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED£1.4bn
- THE BINDING SITE GROUP LIMITED£1.2bn
- WAYVE TECHNOLOGIES LTD£895.2m
- OXFORD NANOPORE TECHNOLOGIES PLC£463.3m
- DIAMOND LIGHT SOURCE LIMITED£343.7m
- THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH£333.4m
- KYOWA KIRIN SERVICES LTD£322.7m
- THE PIRBRIGHT INSTITUTE£322.4m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 5,632. The line on each bar marks the median.
Summary: CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED
What kind of company is it?
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED is a private limited company registered with Companies House under company number 03234033. It was incorporated on 5 Aug 1996. Its status is active. The registered office is in Cambridge (CB2). Its nature of business (SIC 2007) is other research and experimental development on natural sciences and engineering (72190).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files full accounts. Net assets were £3,481,000,000, down 0.5% on the previous year. Figures are available for 2 financial years (2024–2025).
How does it compare with similar companies?
Compared with 5,632 active companies whose first SIC code is 72190: By net assets it ranks higher than 99% of them (median £10,692). By total assets it ranks higher than 99% of them (median £64,502). It is older than 94% of them (median age 7.5 years).
Who runs and controls the company?
One person with significant control is registered.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 29 Aug 2027.
Filed accounts2024–2025
| 2024 † | 2025 † | |
|---|---|---|
| Total assets | 6,994,000,000 | 6,962,000,000 |
| Total liabilities | — | — |
| Net assets / total equity | 3,497,000,000 | 3,481,000,000 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
History
4 events- Financial year 2025 endedAccounts: net assets £3.5bn
- Financial year 2024 endedAccounts: net assets £3.5bn
- Astrazeneca Treasury Limited registered as a person with significant control
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.